Recombinant Human BTLA (31-150) Protein, Fc Tag, 100 µg

Background
B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Source
Recombinant Human BTLA, Fc Tag (BTA-H5256) is expressed from human 293 cells (HEK293). It contains AA Lys 31 - Ser 150 (Accession # AAP44003.1).
Predicted N-terminus: Lys 31

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 40.4 kDa. The protein migrates as 52-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.
 
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM"
Battin, Leitner, Waidhofer-Söllner et al
Front Immunol (2022) 13, 956694
(2)  "Decreased frequency of a novel T-lymphocyte subset, CD3+ CD4- CD7+ CD57- T cells, in hepatitis B virus-related end-stage liver disease might contribute to disease progression"
Yu, Zheng, Zeng et al
J Med Virol (2022)
(3) "Targeted treatment and immunotherapy in high-risk and relapsed/refractory pediatric acute lymphoblastic leukemia"
Graiqevci-Uka, Behluli, Spahiu et al
Curr Pediatr Rev (2022)
Showing 1-3 of 585 papers.